Abstract
Plaque rupture and vascular thrombosis are key initiating factors in the pathogenesis of ischemic complications of percutaneous coronary revascularization (1,2). The central role of platelet activity in this setting is highlighted by the unequivocal benefit of aspirin in preventing death or myocardial infarction among patients undergoing coronary intervention (3). Newer strategies for more potent inhibition of platelet activity at the injured coronary plaque focus on the integrin glycoprotein (GP) IIb/IIIa receptor on the platelet surface membrane, which binds circulating fibrinogen or von Willebrand factor and crosslinks adjacent platelets as the final common pathway to platelet aggregation (4). Pharmacologic compounds directed against GPIIb/IIIa block this receptor, prevent binding of circulating adhesion molecules, and potently inhibit platelet aggregation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105–112.
Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J 1989;117:769–776.
Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714–1719.
Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831–843.
Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92: 2373–2380.
Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.
Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/Illa receptors. J Am Coll Cardiol 1995;26: 1665–1671.
Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680–1688.
Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222–1227.
Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536–542.
EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961.
Lincoff AM, Tcheng JH, Bass TA, et al. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/Illa receptor antibody 7E3 during percutaneous coronary revascularization (abstr). J Am Coll Cardiol 1995;25: 80A.
EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.
EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352: 87–92.
IMPACT II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422–1428.
Phillips DR, Teng W, Arfstent A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with Integrilin. Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488–1494.
Tcheng JE, Talley JD, O’Shea JC, et al. Clinical pharmacology of higher-dose eptifibatide in percutaneous coronary intervention: results of the PRIDE study. Am J Cardiol 2001;88:1097–1102.
ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037–2044.
RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445–1453.
CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429–1435.
Brener SJ, Barr LA, Burchenal JEB, et al., on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98: 734–741.
Neumann F, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915–921.
Montalescot G, Barragan P, Wittenberg O, et al., for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344: 1895–1903.
Stone GW, Grines CL, Cox DA, et al., CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957–966.
Topol EJ, Moliterno DJ, Herrmann HC, et al., for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888–1894.
Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIWIlla receptor blockade by c7E3 Fab (abciximab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30: 149–156.
Steinhubl SR, Lauer MD, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366–1370.
Rao AK, Pratt C, Berke A, et al., for TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1–11.
TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888–1894.
Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary intervention. Circulation 1996;94:1528–1536.
Kugelmass AD, Cohen CJ, Moscucci M, et al. Elevation in creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74:748–754.
Harrington RA, Lincoff AM, Califf RM, et al., for the CAVEAT investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). J Am Coll Cardiol 1995;25:1693–1699.
Kong TQ, Davidson CJ, Meycrs SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461–466.
Tardiff BE, Califf RM, Tcheng JE, et al., for the IMPACT-II Investigators. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II (abstr). J Am Coll Cardiol 1996;27:83A.
Redwood SR, Popma JJ, Kent KK, et al. Predictors of late mortality following ablative new-device angioplasty in native coronary arteries (abstr). J Am Coll Cardiol 1996;27:167A
Topol EJ, Ferguson JJ, Weisman HF, et al., for the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997;278:479–484.
Ellis SG, Lincoff AM, Miller D, et al., for the EPIC and EPILOG Investigators. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol 1998;32:1619–1623.
Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059–2065.
O’Shea JC, Buller CE, Cantor WJ, et al., for the EsPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287: 618–621.
ERASER Investigators. Acute platelet inhibition with abciixmab does not reduce in-stent restenosis (ERASER Study). Circulation 1999;100:799–806.
PURSUIT Trial Investigators. Inhibition of platelet glycoprotein llb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.
PRISM PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.
PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105:316–321.
Kereiakes DJ, Lincoff AM, Miller DP, et al., for the EPILOG Investigators. Abciximab therapy and unplanned coronary stent deployment. Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation 1998;97:857–864.
Marso S, Lincoff A, Ellis S, et al., EPISTENT Investigators. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Circulation 1999;100:2477–2484.
Bhatt D, Marso S, Lincoff A, Wolski K, Ellis S, Topol E. Abciximab reduces mortality in diabetics following percutaneous intervention. JACC 2000;35:922–928.
Ghaffari S, Kereiakes DJ, Lincoff AM, et al., for the EPILOG Investigators. Platelet glycoprotein IIb/ Ma receptor blockade with abciximab reduces ischcmic complications in patients undergoing directional coronary atherectomy. Am J Cardiol 1998;82:7–12.
Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Caller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98:863–874.
Seshiah PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death. Role of macrophage colony stimulating factor and cell contact. Circulation 2002;105:174–180.
Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention. Circulation 2001;103:961–966.
Akkerhuis KM, Deckers JW, Lincoff AM, et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA 2001;286:78–82.
Wagner CL, Cunningham MR, Wyand MS, Weisman HF, Coller BS, Jordan RE. Reversal of the antiplatelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgous monkeys (abstr). Thromb Haemost 1995;73:1313.
Lincoff AM, LeNarz RA, Despotis GJ, et al., for the EPILOG and EPISTENT Investigators. Abciximab and bleeding complications during coronary surgery: results from the EPILOG and EPISTENT trials. Ann Thorac Surg 2000;70:516–526.
Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab glycoprotein IIb/IIIa blockade. Am H J 2000;140:74–80.
Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809–813.
Tcheng JE, Kereiakes DJ, Lincoff AM, et al., for the ReoPro Readminstration Registry Investigators. Abciximab readministration. Results of the ReoPro Readministration Registry. Circulation 2001;104: 870–875.
Topol EJ, Mark DB, Lincoff AM, et al., on behalf of the EPISTENT Investigators. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: one year outcomes and health care economic implications from a multicenter, randomized trial. Lancet 1999;354:2019–2024.
Garbarz E, Farah B, Vuillemenot A, et al. “Rescue” abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998;82:800–803.
Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. “Rescue” utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30:1729–1734.
Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998;114:7288–7418.
Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation 1990;82:1193–1202.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lincoff, A.M., Topol, E.J. (2003). Overview of the Glycoprotein IIb/IIIa Interventional Trials. In: Lincoff, A.M. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-376-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-59259-376-7_8
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-408-1
Online ISBN: 978-1-59259-376-7
eBook Packages: Springer Book Archive